Savara Inc Faces FDA Hurdles Over Manufacturing Data for Respiratory Drug
Savara Inc faces regulatory hurdles with the FDA over its respiratory asset, MOLBREEVI, requiring additional manufacturing data and a meeting to address deficiencies in its marketing application.
2 minutes to read
